0GP7 Stock Overview
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Medivir AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr2.93 |
52 Week High | kr7.38 |
52 Week Low | kr2.93 |
Beta | -0.19 |
1 Month Change | 0% |
3 Month Change | -16.53% |
1 Year Change | n/a |
3 Year Change | -62.86% |
5 Year Change | -85.79% |
Change since IPO | -95.12% |
Recent News & Updates
Recent updates
Shareholder Returns
0GP7 | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0% | -0.2% | 2.3% |
1Y | n/a | -29.5% | 0.6% |
Return vs Industry: Insufficient data to determine how 0GP7 performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0GP7 performed against the UK Market.
Price Volatility
0GP7 volatility | |
---|---|
0GP7 Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 6.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0GP7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0GP7's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 10 | Jens Lindberg | www.medivir.com |
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma.
Medivir AB (publ) Fundamentals Summary
0GP7 fundamental statistics | |
---|---|
Market cap | kr309.24m |
Earnings (TTM) | -kr89.32m |
Revenue (TTM) | kr7.63m |
40.5x
P/S Ratio-3.5x
P/E RatioIs 0GP7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0GP7 income statement (TTM) | |
---|---|
Revenue | kr7.63m |
Cost of Revenue | kr68.87m |
Gross Profit | -kr61.23m |
Other Expenses | kr28.09m |
Earnings | -kr89.32m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 30, 2024
Earnings per share (EPS) | -0.80 |
Gross Margin | -802.20% |
Net Profit Margin | -1,170.21% |
Debt/Equity Ratio | 0% |
How did 0GP7 perform over the long term?
See historical performance and comparison